Search results
Results from the WOW.Com Content Network
Pros and Cons of a Splenectomy. ... Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet ...
The survival time may be longer in large dogs, and the cure rate is 20%. If a tumor is completely removed, usually the pet will receive small doses of radiation in hopes of preventing recurrence. The survival rates are: 1 year: 59%, 3 year: 40%, 5 year: 13%. [14]
MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
Most cases of SPB progress to multiple myeloma within 2–4 years of diagnosis, but the overall median survival for SPB is 7–12 years. 30–50% of extramedullary plasmacytoma cases progress to multiple myeloma with a median time of 1.5–2.5 years. 15–45% of SPB and 50–65% of extramedullary plasmacytoma are disease free after 10 years. [3]
Interacting with dogs in various activities could strengthen activity in brain areas associated with relaxation and focus, a new study has found. Interacting with dogs may affect multiple areas of ...
According to the International Myeloma Foundation, Black people will make up nearly a quarter (24%) of all newly diagnosed cases by 2034 if nothing is done — an astonishing rate given that Black ...
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.